Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

PHASE2UnknownINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

March 31, 2004

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

DN-101 (calcitriol)

Trial Locations (10)

14263

Roswell Park Cancer Institute, Buffalo

33612

James A. Haley Veterans Hospital, Tampa

35216

Clinical Research Consultants, Inc., Hoover

38104

Boston Baskin Cancer Group, Memphis

44195

The Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland

60612

Rush Cancer Institute MDS Center, Chicago

77030

University of Texas - MD Anderson Cancer Center, Houston

94143

University of California, San Francisco, San Francisco

97201

Oregon Health Sciences University, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novacea

INDUSTRY

NCT00057031 - Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS) | Biotech Hunter | Biotech Hunter